WallStSmart
VYGR

Voyager Therapeutics Inc

NASDAQ: VYGR · HEALTHCARE · BIOTECHNOLOGY

$3.73
+2.47% today

Updated 2026-04-30

Market cap
$224.69M
P/E ratio
P/S ratio
5.57x
EPS (TTM)
$-2.04
Dividend yield
52W range
$3 – $6
Volume
0.7M

Voyager Therapeutics Inc (VYGR) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
-2.6%
Last 4 quarters
Revenue YoY growth
+144.3%
Most recent quarter
EPS YoY growth
+20.3%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+9.4%
Last 2 reports
Positive reaction rate
100%
2 of 2 quarters
Largest single-day move
+18.0%
2026-03-10
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-10$-0.47+7.9%$4.11$4.85+18.0%
2025-11-10$-0.47+9.6%$4.23$4.26+0.7%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.51$-0.47+7.9%$15.34M+144.3%
2025-09-30$-0.52$-0.47+9.6%$13.37M-45.7%
2025-06-30$-0.53$-0.57-7.5%$5.20M-82.4%
2025-03-31$-0.44$-0.53-20.5%$6.47M-66.8%
2024-12-31$-0.35$-0.59-68.4%$6.28M-93.0%
2024-09-30$-0.45$-0.16+64.4%$24.63M+433.8%
2024-06-30$-0.41$-0.18+56.1%$29.58M+509.5%
2024-03-31$-0.44$-0.20+54.5%$19.52M-87.0%
2023-12-31$-0.29$1.25+531.0%$90.06M
2023-09-30$-0.58$-0.59-1.7%$4.61M
2023-06-30$-0.57$-0.51+10.5%$4.85M
2023-03-31$0.77$2.94+281.8%$150.48M

Frequently asked questions

Has Voyager Therapeutics Inc beaten earnings estimates?
Voyager Therapeutics Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of -2.6% over the last 4 quarters.
How does VYGR stock react to earnings?
VYGR stock has moved an average of +9.4% in the trading day following earnings over its last 2 reports, with positive reactions in 100% of those quarters.
What is Voyager Therapeutics Inc's revenue growth rate?
Voyager Therapeutics Inc reported year-over-year revenue growth of +144.3% in its most recent quarter, with EPS growing +20.3% year-over-year.